HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

Key Points

• HC Wainwright cut Savara’s FY2029 EPS forecast to $0.09 from $0.11, while projecting FY2030 EPS of $0.37. The revision is notably above the current full-year consensus estimate of a $0.57 loss per share.
• Savara reported a quarterly loss of $0.16 per share, missing analysts’ $0.14-loss consensus by $0.02.
• Shares rose 2.3% to $5.70, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $10.14; institutional investors own nearly 88% of the stock.

Savara Inc. (NASDAQ:SVRA - Free Report) - Research analysts at HC Wainwright dropped their FY2029 EPS estimates for Savara in a research report issued on Wednesday, August 12th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $0.09 for the year, down from their prior forecast of $0.11. The consensus estimate for Savara's current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Savara's FY2030 earnings at $0.37 EPS.

Savara (NASDAQ:SVRA - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02).

Several other equities analysts have also recently weighed in on the company. Wall Street Zen upgraded Savara from a "sell" rating to a "hold" rating in a report on Saturday, June 13th. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They issued an "outperform" rating and a $11.00 price target for the company. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Savara presently has a consensus rating of "Moderate Buy" and an average price target of $10.14.

Savara Trading Up 2.3%

Shares of NASDAQ:SVRA opened at $5.70 on Thursday. The company's 50-day moving average price is $5.65 and its two-hundred day moving average price is $5.49. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. Savara has a one year low of $2.43 and a one year high of $7.01. The stock has a market capitalization of $1.17 billion, a PE ratio of -9.83 and a beta of 0.29.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in Savara by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 170,176 shares of the company's stock valued at $388,000 after purchasing an additional 16,634 shares during the last quarter. Prudential Financial Inc. bought a new stake in Savara in the second quarter valued at approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Savara in the second quarter valued at approximately $201,000. Invesco Ltd. lifted its position in shares of Savara by 35.4% in the second quarter. Invesco Ltd. now owns 120,891 shares of the company's stock valued at $276,000 after buying an additional 31,633 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company's stock worth $118,000 after acquiring an additional 6,449 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source